Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate

Orum announced that the first patient has been dosed in a Phase 1 clinical trial evaluating ORM-1153, the Company’s investigational CD123-GSPT1 DAC.

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.